Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.33 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | NOS1 | P29475 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.31 |
| ▸ | NOS3 | P29474 | 1/20 | 0.30 |
| ▸ | NOS2 | P35228 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4981459 | 0.77 | LMNA (0.41) | LMNAKDM4EMAPTNOS1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL27505322 | 0.75 | LMNA (0.40) | LMNAKDM4EMAPTNOS1SMN1; SMN2 | |
| SCHEMBL11763045 | 0.72 | MAPT (0.46) | LMNAKDM4EMAPTNOS1SMN1; SMN2 | |
| SCHEMBL14276072 | 0.69 | SMN1; SMN2 (0.42) | LMNAKDM4EMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL14000831 | 0.69 | SMN1; SMN2 (0.42) | LMNAKDM4EMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL6445297 | 0.67 | KDM4E (0.44) | LMNAKDM4EMAPTNOS1SMN1; SMN2 | |
| SCHEMBL2955960 | 0.67 | MAPT (0.35) | LMNAKDM4EMAPTNOS1SMN1; SMN2 | |
| Bromide SCHEMBL9290820 | 0.66 | KDM4E (0.43) | LMNAKDM4EMAPTNOS1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL7327757 | 0.65 | MAPT (0.36) | LMNAKDM4EMAPTSMN1; SMN2ALDH1A1 | |
| SCHEMBL9861592 | 0.65 | KDM4E (0.49) | LMNAKDM4ESMN1; SMN2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1576093-A4 | 3-DEOXYGLUCOSONE AND SKIN | DYNAMIS THERAPEUTICS INC (US) | 2009-07-08 | — | — | EP | claimed |
| US-20070065443-A1 | Fructoseamine 3 kinase and the formation of collagen and elastin | DYNAMIS THERAPEUTICS, INC. | 2007-03-22 | — | — | US | claimed |
| EP-1753861-A2 | FRUCTOSEAMINE 3 KINASE AND THE FORMATION OF COLLAGEN AND ELASTIN | Dynamis Therapeutics, Inc. (US) | 2007-02-21 | — | — | EP | claimed |
| EP-1576093-A2 | 3-DEOXYGLUCOSONE AND SKIN | Dynamis Therapeutics, Inc. (US) | 2005-09-21 | — | — | EP | claimed |
| WO-2005079463-A2 | FRUCTOSEAMINE 3 KINASE AND THE FORMATION OF COLLAGEN AND ELASTIN | DYNAMIS THERAPEUTICS, INC. (US) | 2005-09-01 | — | — | WO | claimed |
| US-20050159383-A1 | Administering enzyme inhibitors; wrinkling and aging resistance; prevents formation Advanced Glycation End Products (AGEs) | DYNAMIS THERAPEUTICS, INC. | 2005-07-21 | — | — | US | claimed |
| US-20030219440-A1 | 3-deoxyglucosone and skin | DYNAMIS THERAPEUTICS, INC. | 2003-11-27 | — | — | US | claimed |
| WO-2003089601-A2 | 3-DEOXYGLUCOSONE AND SKIN | DYNAMIS THERAPEUTICS, INC. (US) | 2003-10-30 | — | — | WO | claimed |
| US-20100310482-A1 | 3-Deoxyglucosone And Skin | DYNAMIS THERAPEUTICS, INC. (US) | 2010-12-09 | — | — | US | disclosed |
| US-7749503-B2 | 3-deoxyglucosone and skin | DYNAMIS THERAPEUTICS, INC. (US) | 2010-07-06 | — | — | US | disclosed |
| US-7671019-B2 | Administering enzyme inhibitors; wrinkling and aging resistance; prevents formation Advanced Glycation End Products (AGEs) | DYNAMIS THERAPEUTICS, INC. (US) | 2010-03-02 | — | — | US | disclosed |
| US-7622117-B2 | 3-deoxyglucosone and skin | DYNAMIS THERAPEUTICS, INC. (US) | 2009-11-24 | — | — | US | disclosed |
| US-20080292568-A1 | 3-Deoxyglucosone and skin | DYNAMIS THERAPEUTICS, INC. (US) | 2008-11-27 | — | — | US | disclosed |
| US-20070065443-A1 | Fructoseamine 3 kinase and the formation of collagen and elastin | DYNAMIS THERAPEUTICS, INC. | 2007-03-22 | — | — | US | disclosed |
| US-20050159383-A1 | Administering enzyme inhibitors; wrinkling and aging resistance; prevents formation Advanced Glycation End Products (AGEs) | DYNAMIS THERAPEUTICS, INC. | 2005-07-21 | — | — | US | disclosed |
| US-20030219440-A1 | 3-deoxyglucosone and skin | DYNAMIS THERAPEUTICS, INC. | 2003-11-27 | — | — | US | disclosed |
| EP-1175155-A1 | METHOD FOR REDUCING A SUSCEPTIBILITY TO TUMOR FORMATION INDUCED BY 3-DEOXYGLUCOSONE AND PRECURSORS THEREOF | FOX CHASE CANCER CENTER (US) | 2002-01-30 | — | — | EP | disclosed |
| WO-2000062626-A1 | METHOD FOR REDUCING A SUSCEPTIBILITY TO TUMOR FORMATION INDUCED BY 3-DEOXYGLUCOSONE AND PRECURSORS THEREOF | FOX CHASE CANCER CENTER (US) | 2000-10-26 | — | — | WO | disclosed |
| US-5612332-A | INHIBITING PROTEIN GLYCOSYLATION | ALTEON INC. (US) | 1997-03-18 | — | — | US | disclosed |
| WO-1996040663-A1 | DI- AND TRI-AMINOGUANIDINES AND THEIR USE TO INHIBIT THE ADVANCED GLYCOSYLATION OF PROTEINS | ALTEON INC. (US) | 1996-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070065443-A1 | Fructoseamine 3 kinase and the formation of collagen and elastin | FN3K, PDXK, COLGALT1 | LMNA 1512/4885KDM4E 1956/4885MAPT 677/4885 |
| US-20100310482-A1 | 3-Deoxyglucosone And Skin | DPM1, G6PD, UGGT1 | LMNA 2324/4885KDM4E 897/4885MAPT 3453/4885 |
| US-20080292568-A1 | 3-Deoxyglucosone and skin | DPM1, G6PD, UGGT1 | LMNA 2324/4885KDM4E 897/4885MAPT 3453/4885 |
| US-20030219440-A1 | 3-deoxyglucosone and skin | DPM1, G6PD, UGGT1 | LMNA 2324/4885KDM4E 897/4885MAPT 3453/4885 |
| US-20050159383-A1 | Administering enzyme inhibitors; wrinkling and aging resistance; prevents formation Advanced Glycation End Products (AGEs) | AGER, GLA, GALE | LMNA 1248/4885KDM4E 441/4885MAPT 2715/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.